Effect of Intracameral Ophthalmic Cefuroxime Solution (Aprokam®) in the Prophylaxis of Cataract Surgery in Patients with Keratoplasty

Abstract

Development of endophthalmitis during cataract surgery is one of the most severe complications and it may also result in blindness and globe loss. In this retrospective study, patients who had undergone penetrating keratoplasty and for whom phacoemulsification surgery was performed due to cataract and an intracameral ophthalmic cefuroxime solution (Aprokam®) was administered for prophylaxis were evaluated in comparison with patients with cataract without keratoplasty. There was no significant effect of the prophylactic intracameral use of ophthalmic cefuroxime solution (Aprokam®) on the endothelial cells which was used in patients with keratoplasty for whom cataract surgery was performed. Background: Development of endophthalmitis during cataract surgery is one of the most severe complications and it may also result in blindness and globe loss.Aims: To evaluate the effect of an ophthalmic cefuroxime solution (Aprokam®) that is prophylactically used in phacoemulsification surgery performed due to cataract that eventually occurs in patients with or without penetrating keratoplasty.Study Design: Case-control study.Methods: In this retrospective study, patients who had undergone penetrating keratoplasty and for whom phacoemulsification surgery was performed due to cataract and an intracameral ophthalmic cefuroxime solution (Aprokam®) was administered for prophylaxis were evaluated in comparison with patients with cataract without keratoplasty. The following parameters were evaluated: postoperative anterior chamber reaction, intraocular pressure, best corrected visual acuity, corneal endothelial cell density, and central corneal thickness alterations.Results: A total of 42 patients (18 males, 24 females) with keratoplasty and 42 patients (17 males, 25 females) without keratoplasty were included in this study. An increase in visual acuity was observed in all the patients after cataract surgery (p<0.001). The mean corneal endothelial cell densitys were determined to be 2437.20±148.5 cells/mm2 preoperatively in the study group and 2807.1±152.4 cells/mm2 preoperatively in the control group. The mean corneal endothelial cell densitys were determined to be 2103.85±196.5 cells/mm2 after the first postoperative month (p<0.001) in the study group and 2755.92±182.7 cells/mm2 in the control group (p=0.17). The mean central corneal thickness in the study group were 565.78±11.5 μm preoperatively and 584.65±12.7 μm after the first postoperative month (p<0.001). No difference was observed in the control group in terms of preoperative and postoperative central corneal thickness and endothelial cell density. There was no significant difference between the groups in terms of the intraocular pressure, anterior chamber reaction.Conclusion: There was no significant effect of the prophylactic intracameral use of ophthalmic cefuroxime solution (Aprokam®) on the endothelial cells which was used in patients with keratoplasty for whom cataract surgery was performed.

Keywords

• Aprokam, cefuroxime, cataract, keratoplasty, prophylaxis

Kaynakça

1. 1. Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Newton J, Miller D. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139:983-7.
2. 2. Linertova R, Abreu-Gonzalez R, Garcia-Perez L, Alonso-Plasencia M, CordovesDorta LM, Abreu-Reyes JA, et al. Intracameral cefuroxime and moxifloxacin used as endophthalmitis prophylaxis after cataract surgery: systematic review of effectiveness and cost-effectiveness. Clin Ophthalmol 2014;8:1515-22. PubMed PMID: 25152613. Pubmed Central PMCID: PMC4140229. Epub 2014/08/26.eng
3. 3. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007;33:978-88.
4. 4. Aprokam 50 mg powder for solution for injection: summary of product characteristics. France: Laboratoires Thea; 2012.
5. 5. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs 2001;61:1455-500.
6. 6. Haripriya A. Antibiotic prophylaxis in cataract surgery - An evidence-based approach. Indian J Ophthalmol 2017;65:1390-5.
7. 7. Haripriya A, Chang DF. Intracameral antibiotics during cataract surgery: evidence and barriers. Curr Opin Ophthalmol 2018;29:33-9.
8. 8. McCarey BE, Edelhauser HF, Lynn MJ. Review of corneal endothelial specular microscopy for FDA clinical trials of refractive procedures, surgical devices, and new intraocular drugs and solutions. Cornea 2008;27:1-16.

9. 9. Gupta MS, McKee HD, Saldana M, Stewart OG. Macular thickness after cataract surgery with intracameral cefuroxime. J Cataract Refract Surg 2005;31:1163-6.
10. 10. Montan PG, Wejde G, Setterquist H, Rylander M, Zetterström C. Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg 2002;28:982-7.
11. 11. Ahmed II, Kranemann C, Chipman M, Malam F. Revisiting early postoperative follow-up after phacoemulsification. J Cataract Refract Surg 2002;28:100-8.
12. 12. Behndig A, Lundberg B. Transient corneal edema after phacoemulsification: comparison of 3 viscoelastic regimens. J Cataract Refract Surg 2002;28:1551-6.
13. 13. Delyfer MN, Rougier MB, Leoni S, Zhang Q, Dalbon F, Colin J, et al. Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg 2011;37:271-8.
14. 14. Qureshi F, Clark D. Macular infarction after inadvertent intracameral cefuroxime. J Cataract Refract Surg 2011;37:1168-9.
15. 15. Sakarya Y, Sakarya R. Cefuroxime dilution error. Eur J Ophthalmol 2010;20:460-1.
16. 16. Yunliang S, Yuqiang H, Ying-Peng L, Ming-Zhi Z, Lam DS, Rao SK. Corneal endothelial cell density and morphology in healthy Chinese eyes. Cornea 2007;26:130-2.
17. 17. Bourne WM, Nelson LR, Hodge DO. Continued endothelial cell loss ten years after lens implantation. Ophthalmology 1994;101:1014-22.
18. 18. Shimmura S, Ohashi Y, Shiroma H, Shimazaki J, Tsubota K. Corneal opacity and cataract: triple procedure versus secondary approach. Cornea 2003;22:234-8.
19. 19. Hayashi K, Hayashi H, Nakao F, Hayashi F. Risk factors for corneal endothelial injury during phacoemulsification. J Cataract Refract Surg 1996;22:1079-84.